Scripps Health will begin selling skin creams developed by Encinitas-based Sente Inc., a privately held company with deep roots in San Diego’s biopharmaceutical community.
Sente’s founder, Kleanthis Xanthopoulos, is also the CEO of San Diego-based Regulus Therapeutics Inc. Regulus, a publicly traded company with a market capitalization of $278 million, develops drugs based on RNA therapy.
Under the new contract, Senté will sell and distribute its products to Scripps patients throughout San Diego and Chula Vista. Financial details were not disclosed.
Senté, called a cosmeceutical company because it melds cosmetics with pharmaceuticals, said in a statement that it’s the only company that uses a compound called heparan sulfate in skin cream. The substance naturally helps with cell regeneration, according to the company.
“As a Scripps physician, it is my goal to provide patients with high-quality outcomes through a variety of treatment options,” Edward Ross, director of Scripps Laser and Cosmetic Dermatology Center, said, in a statement. “Recent studies have validated the importance of heparan sulfate in repairing skin conditions related to UV exposure and aging — I am pleased to offer this treatment option to my patients.”
– SDBJ Staff Report